Table 1.
Baseline characteristics of patients with mCRC according to MPV levels
| Variables | Total n (%) | MPV ≥ 9.75 | MPV<9.75 | P value |
|---|---|---|---|---|
| Age (years) | 0.6329 | |||
| ≤65 | 209(79.2%) | 135(78.0%) | 74(81.3%) | |
| >65 | 55(20.8%) | 38(22.0%) | 17(18.7%) | |
| Gender | 0.9753 | |||
| Male | 157(59.4%) | 103(59.5%) | 54(59.3%) | |
| Female | 107(40.6%) | 70(40.5%) | 37(40.7%) | |
| Location | 0.5950 | |||
| Colon | 164 (62.3%) | 106(61.3%) | 59 (64.8%) | |
| Rectum | 99 (37.7%) | 67 (38.7%) | 32(35.2%) | |
| Regimen | 0.3024 | |||
| Oxaliplatin | 125(46.2%) | 86(49.7%) | 39(42.9%) | |
| Irinotecan | 142(53.8%) | 87(50.3%) | 52(57.1%) | |
| Histology | 0.3593 | |||
| adenocarcinoma | 239(90.5%) | 161(93.1%) | 78(85.7%) | |
| mucinous adenocarcinoma | 15(5.7%) | 7(4.0%) | 8(8.8%) | |
| signet-ring cell carcinoma | 4(1.5%) | 2(1.2%) | 2(2.2%) | |
| NK | 6(2.3%) | 3(1.7%) | 3(3.3%) | |
| Metastasis pattern | 0.4852 | |||
| simultaneous | 146(55.3%) | 93 (53.8%) | 53(58.2%) | |
| metachronous | 118(44.7%) | 80(46.2%) | 38(41.7%) | |
| Efficacy | 0.0166 | |||
| CR + PR | 84(31.8%) | 65(37.6%) | 19(20.9%) | |
| SD | 132(50.0%) | 81(46.8%) | 51(56.0%) | |
| PD | 27(10.2%) | 18(10.4%) | 9(9.9%) | |
| NK | 21(8.0%) | 9(5.2%) | 12(13.2%) |
Abbreviations: NK not known, CR complete response, SD stable disease, PD progression disease